These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 2106400)
1. Adverse hemodynamic effects of antiarrhythmic drugs in congestive heart failure. Hammermeister KE Circulation; 1990 Mar; 81(3):1151-3. PubMed ID: 2106400 [No Abstract] [Full Text] [Related]
2. Comparative hemodynamic effects of procainamide, tocainide, and encainide in severe chronic heart failure. Gottlieb SS; Kukin ML; Medina N; Yushak M; Packer M Circulation; 1990 Mar; 81(3):860-4. PubMed ID: 2106401 [TBL] [Abstract][Full Text] [Related]
3. Congestive heart failure induced by six of the newer antiarrhythmic drugs. Ravid S; Podrid PJ; Lampert S; Lown B J Am Coll Cardiol; 1989 Nov; 14(5):1326-30. PubMed ID: 2509529 [TBL] [Abstract][Full Text] [Related]
8. Hemodynamic effects of antiarrhythmic drugs. Block PJ; Winkle RA Am J Cardiol; 1983 Sep; 52(6):14C-23C. PubMed ID: 6414278 [TBL] [Abstract][Full Text] [Related]
9. Antiarrhythmic drug combinations in the treatment of ventricular tachycardia. Ross DL; Sze DY; Keefe DL; Swerdlow CD; Echt DS; Griffin JC; Winkle RA; Mason JW Circulation; 1982 Dec; 66(6):1205-10. PubMed ID: 6814784 [TBL] [Abstract][Full Text] [Related]
10. Adverse hemodynamic and clinical effects of encainide in severe chronic heart failure. Gottlieb SS; Kukin ML; Yushak M; Medina N; Packer M Ann Intern Med; 1989 Apr; 110(7):505-9. PubMed ID: 2493762 [TBL] [Abstract][Full Text] [Related]
11. Clinical profiles of newer class I antiarrhythmic agents--tocainide, mexiletine, encainide, flecainide and lorcainide. Pottage A Am J Cardiol; 1983 Sep; 52(6):24C-31C. PubMed ID: 6414279 [TBL] [Abstract][Full Text] [Related]
12. The use of antiarrhythmic agents in heart failure: implications of CAST. Gottlieb SS Am Heart J; 1989 Nov; 118(5 Pt 1):1074-7. PubMed ID: 2510486 [No Abstract] [Full Text] [Related]
13. A review of the uses and limitations of tocainide--a class IB antiarrhythmic agent. Morganroth J; Nestico PF; Horowitz LN Am Heart J; 1985 Oct; 110(4):856-63. PubMed ID: 3931446 [TBL] [Abstract][Full Text] [Related]
14. Antiarrhythmic drug therapy. Recent advances and current status. Somberg J Cardiology; 1985; 72(5-6):329-48. PubMed ID: 2866841 [TBL] [Abstract][Full Text] [Related]
15. Second generation antiarrhythmic agents: have we reached antiarrhythmic Nirvana? Horowitz LN; Morganroth J J Am Coll Cardiol; 1987 Feb; 9(2):459-63. PubMed ID: 3100601 [No Abstract] [Full Text] [Related]
18. Cardiac electrophysiology of four new antiarrhythmic drugs--encainide, flecainide, lorcainide and tocainide. Camm AJ Eur Heart J; 1984 Sep; 5 Suppl B():75-9. PubMed ID: 6437820 [No Abstract] [Full Text] [Related]
19. Chemistry, pharmacology, antiarrhythmic efficacy and adverse effects of tocainide hydrochloride, an orally active structural analog of lidocaine. Alpert JS; Haffajee CI; Young MD Pharmacotherapy; 1983; 3(6):316-23. PubMed ID: 6419205 [TBL] [Abstract][Full Text] [Related]
20. Electrocardiographic and hemodynamic effects of tocainide (W-36095) in man. Swedberg K; Pehrson J; Rydén L Eur J Clin Pharmacol; 1978 Nov; 14(1):15-9. PubMed ID: 729602 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]